



Prana to be Featured in Alzheimer's Disease Conference Call

MELBOURNE, Australia – March 14, 2008 – Prana Biotechnology Limited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that the Company will be featured on a conference call on Friday, March 14 at 1 p.m. EDT, coordinated by Rodman & Renshaw, to discuss innovative approaches in Alzheimer's disease therapy.

Prana will highlight recent successful results from its Phase IIa clinical trial, and assess new approaches in treating Alzheimer's disease. To dial into the call, please contact:

US Toll-Free: (866) 463-5401, International: (212) 457-9857 Passcode: 853067

A replay will be available for one week starting at 3:00pm EDT:
(866) 439-4554 or (212) 457-9844, Passcode: 354581

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's Disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information, please visit the Company's web site at www.pranabio.com

Contacts:

Prana Biotechnology Limited
T: +61 3 9349 4906